Picture loading failed.

Anti-CD22 therapeutic antibody (Pre-made Inotuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-275-1mg 1mg 3090
GMP-Bios-ab-275-10mg 10mg 21890
GMP-Bios-ab-275-100mg 100mg 148000
GMP-Bios-ab-275-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD22 therapeutic antibody (Pre-made Inotuzumab biosimilar,Whole mAb ADC)
INN Name Inotuzumab
TargetCD22
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2004
Year Recommended2005
CompaniesAlliance for Clinical Trials in Oncology;Cancer Research UK;Case Comprehensive Cancer Center;Children's Oncology Group;Erasmus MC;M. D. Anderson Cancer Center;National Cancer Institute (USA);Pfizer;SWOG;University College London;University of Texas M. D. Anderson Cancer Center;Celltech Group
Conditions ApprovedPrecursor cell lymphoblastic leukaemia-lymphoma
Conditions ActivePrecursor B-cell lymphoblastic leukaemia-lymphoma;Chronic myeloid leukaemia
Conditions DiscontinuedAcute biphenotypic leukaemia;Burkitt's lymphoma;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma
Development Techna